학술논문
ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC).
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2024 Supplement 3, Vol. 42, p475-475, 151p
Subject
Language
ISSN
0732183X